Tower Research Capital LLC (Trc) Cardiff Oncology, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 5,877 shares of CRDF stock, worth $24,918. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,877
Previous 4,697
25.12%
Holding current value
$24,918
Previous $12,000
108.33%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding CRDF
# of Institutions
125Shares Held
25.3MCall Options Held
866KPut Options Held
203K-
Commodore Capital LP New York, NY5.38MShares$22.8 Million2.34% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$11.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.28MShares$9.69 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.54MShares$6.52 Million0.18% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.44MShares$6.12 Million3.38% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $184M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...